Drug Profile
Research programme: skin disorder therapeutics - DermAct
Alternative Names: AM031/032Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator DermAct Pharmaceutical
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Skin-disorders in USA
- 26 Mar 2009 Preclinical trials in Skin disorders in USA (unspecified route)